1. suspension of major events: the pharmaceutical innovation etf needs to be suspended for a period of time for related operations because it is planning major events, such as asset restructuring and mergers and acquisitions.
2. Temporary suspension: When the transaction price of pharmaceutical innovation etf in the secondary market has a substantial premium, and the transaction price obviously deviates from the net value of fund shares on the previous valuation date, the suspension will be temporarily suspended to maintain market order and investors' interests.